SEC Form 4 · accession 0001209191-15-037172
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Apr 27, 2015
Accepted (ET)
Apr 29, 2015 · 8:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 27, 2015 | G | 150 | $0.00 | D | 138,120 | D | |
| Common Stock | Apr 27, 2015 | M | 18,312 | $53.74 | A | 156,432 | D | |
| Common Stock | Apr 27, 2015 | M | 15,563 | $45.11 | A | 171,995 | D | |
| Common Stock | Apr 27, 2015 | M | 17,000 | $77.31 | A | 188,995 | D | |
| Common StockF3,F4 | Apr 27, 2015 | S | 21,480 | $127.49 | D | 167,515 | D | |
| Common StockF4,F5 | Apr 27, 2015 | S | 12,933 | $128.17 | D | 154,582 | D | |
| Common StockF4,F6 | Apr 27, 2015 | S | 1,100 | $129.30 | D | 153,482 | D | |
| Common StockF4,F7 | Apr 27, 2015 | S | 11,321 | $130.33 | D | 142,161 | D | |
| Common StockF4,F8 | Apr 27, 2015 | S | 4,230 | $131.27 | D | 137,931 | D | |
| Common StockF4,F9 | Apr 27, 2015 | S | 6,316 | $132.44 | D | 131,615 | D | |
| Common StockF4,F10 | Apr 27, 2015 | S | 3,400 | $133.34 | D | 128,215 | D | |
| Common StockF4,F11 | Apr 27, 2015 | S | 700 | $134.05 | D | 127,515 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F12 | $53.74 | Apr 27, 2015 | M | 18,312 | D | — | Sep 3, 2022 | Common Stock | 18,312 | 27,188 | D |
| Stock Option (right to buy)F13 | $45.11 | Apr 27, 2015 | M | 15,563 | D | — | Feb 4, 2023 | Common Stock | 15,563 | 45,312 | D |
| Stock Option (right to buy)F14 | $77.31 | Apr 27, 2015 | M | 17,000 | D | — | Feb 4, 2024 | Common Stock | 17,000 | 51,000 | D |
Explanation of responses
- F1Represents a gift made to a charitable organization.
- F10Open market sales reported on this line occurred at a weighted average price of $133.34 (range $132.98 to $133.92).
- F11Open market sales reported on this line occurred at a weighted average price of $134.05 (range $133.99 to $134.09).
- F12The option vests in 16 quarterly installments from 09/04/2012.
- F13The option vests in 16 quarterly installments from 02/05/2013.
- F14The option vests in 16 quarterly installments from 02/05/2014.
- F2Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F3Open market sales reported on this line occurred at a weighted average price of $127.49 (range $126.88 to $127.87).
- F4Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F5Open market sales reported on this line occurred at a weighted average price of $128.17 (range $127.88 to $128.82).
- F6Open market sales reported on this line occurred at a weighted average price of $129.30 (range $128.93 to $129.90).
- F7Open market sales reported on this line occurred at a weighted average price of $130.33 (range $129.94 to $130.88).
- F8Open market sales reported on this line occurred at a weighted average price of $131.27 (range $130.94 to $131.92).
- F9Open market sales reported on this line occurred at a weighted average price of $132.44 (range $131.94 to $132.91).